Key Highlights

  • Instinct Bio Technical began trading on Nasdaq on July 24, 2026 after a SPAC Merger valued at a pro forma Enterprise value of about $288 million, but third-party data showed no reported Revenue as of September 24, 2026.
  • DocGo reported Q2 2026 total revenue of $73.4 million, down from $80.4 million a year earlier, as Mobile Health Services revenue fell 30.5% amid the wind-down of migrant-related programs.
  • DocGo narrowed its 2026 revenue guidance to $305 million to $310 million and widened its expected adjusted EBITDA loss to $17 million to $22 million.
  • DocGo is pursuing an Acquisition of Hicuity Health, a Tele-ICU and virtual nursing provider generating about $65 million in trailing twelve-month revenue, financed partly through $52 million in assumed debt.

Instinct Bio Technical (NASDAQ:BIOT) and DocGo (NASDAQ:DCGO) both sit under the healthcare label, but little else connects them. One is a Tokyo-based regenerative medicine and stem cell skincare company that reached Nasdaq through a SPAC merger in July 2026. The other is a U.S. provider of medical transportation and mobile health services now repositioning around virtual and in-home care. The sharp contrast is what makes the pairing useful.

Instinct Bio Technical (NASDAQ:BIOT): A New Listing Built on Stem Cell Products

Instinct Bio Technical Company Holdings completed its Business combination with Relativity Acquisition Corp. on July 23, 2026, and its shares began trading on Nasdaq under the ticker BIOT the next day, with warrants listed as BIOTW. The operating business, formerly known as Instinct Brothers, describes itself as a vertically integrated regenerative medicine and longevity platform spanning stem cell research, in-house manufacturing, premium skincare brands and clinic services under the GENREVER Clinic name. The closing announcement cited a pro forma enterprise value of about $288 million.

Since listing, news flow has centered on financing and partnerships. On July 28, 2026, the company disclosed an indicative term sheet for an Equity purchase Facility of up to $150 million over three years, priced at a discount to the volume-weighted average price, while cautioning that definitive documents might not be signed. A September 4 update said construction had begun on a 213-square-meter clinic in South Jakarta, targeted to open at the end of December 2026, with monthly membership tiers of $400, $1,000 and $3,000, alongside Indonesian cosmetics work with PT Parva Candela.

Post-listing financial reporting is harder to find. Third-party data as of September 24, 2026 showed no reported revenue or Earnings for the listed entity and a Market Value of roughly $12 million, far below the closing valuation. Investors would need to consult the audited statements in the merger registration statement and watch for the first periodic report.

DocGo (NASDAQ:DCGO): A Shrinking Contract Business and a Pivot Toward Virtual Care

DocGo's recent story is one of replacing lost revenue. For the second quarter ended June 30, 2026, the company reported total revenue of $73.4 million, down from $80.4 million a year earlier. Medical Transportation Services revenue rose 4.8% to $52.0 million, while Mobile Health Services revenue fell 30.5% to $21.4 million as migrant-related programs wound down. Excluding those programs, management said revenue grew 19%. The net loss widened to $18.0 million from $13.3 million, and adjusted EBITDA was a loss of $6.3 million. For the first half of 2026, revenue was $149.0 million and the net loss was $34.7 million.

In the August 17 release, the 2026 revenue range was narrowed to $305 million to $310 million, while expected adjusted EBITDA was cut to a loss of $17 million to $22 million from a prior $5 million to $10 million loss. At June 30, DocGo held about $48.1 million in total cash, restricted cash and investments, of which $25.2 million was unrestricted.

The bigger strategic move is a pending acquisition of Hicuity Health, which provides Tele-ICU, virtual nursing and telemetry monitoring to hospitals. DocGo said Hicuity generated roughly $65 million of trailing twelve-month revenue and $4.5 million of adjusted EBITDA; the deal involves assuming about $52 million of Debt held by Perceptive Advisors, which also committed up to $50 million of new debt financing. Separately, after a January 2026 Nasdaq minimum bid notice, DocGo received a second compliance period running to January 25, 2027, and stockholders approved a reverse split range of 1-for-5 to 1-for-10.

Why Business Maturity Matters in This Comparison

The clearest difference is the amount of evidence each company offers. DocGo reports quarterly segment revenue, guidance and cash, so claims can be tested against numbers every three months. Instinct Bio is at a stage where the market mostly sees plans: a clinic under construction, cosmetics candidates targeted for production within 2026 subject to regulatory approval, and a financing facility that is not yet definitive.

  • Reported financials: When Instinct Bio files its first periodic report as a listed company, and what revenue and cash it shows.
  • Core growth at DocGo: Whether non-migrant revenue keeps growing fast enough to offset the wind-down.
  • Financing terms: How much dilution the Instinct Bio equity line could create, and how much Leverage DocGo takes on with Hicuity.
  • Listing status: DocGo's route to regaining $1.00 bid compliance before January 2027, and Instinct Bio's share price relative to the same threshold.

Using the Nasdaq Composite as a Benchmark

The Nasdaq Composite offers a broad, diversified reference point for returns and volatility. Comparing either stock with the index over the same period helps separate company-specific moves from general market direction. The index is used here only as a comparison benchmark, not as a claim that either company is a member of it.

Very small companies tend to swing far more than a broad index and are more exposed to dilution from equity lines and convertible financing, so a stock trailing the Composite may reflect financing pressure rather than sector trends.

Risks

For Instinct Bio, the main risks are limited public financial disclosure, reliance on a financing facility still at the term-sheet stage, regulatory approvals for new cosmetic products, and opening clinics in a new country.

For DocGo, the risks include continued net losses, a lowered adjusted EBITDA outlook, integration and debt risk tied to Hicuity, and a possible reverse split.

Two Healthcare Stocks Positioned as Differently as Possible

DocGo is an established operator in transition, with a growing transportation business, a shrinking contract segment and a pending bet on virtual care. Instinct Bio is a newly listed company whose story is largely forward-looking and whose finances are not yet well documented in public reports. The comparison shows how differently two healthcare stocks can be positioned.